Results 11 to 20 of about 206,766 (202)
We are now near the end of the second year of the COVID-19 pandemic, and it has been a year since the first International System Safety Society (ISSS) Conference coronavirus presentation. This past year has seen the development and distribution of several vaccines, as predicted in the previous publication about the pandemic.
Susan Hahné +2 more
core +5 more sources
Major vaccine safety controversies have arisen in several countries beginning in the last decades of 20th century. Such periodic vaccine safety controversies are unlikely to go away in the near future as more national immunization programs mature with ...
core +12 more sources
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are proposed for the treatment of acute lung injury and atopic dermatitis. To advance hUC-MSC entry into clinical trials, the effects of hUC-MSCs on the general toxicity, immune perturbation and ...
Wei Pan +25 more
doaj +1 more source
Evidence and guidance on vaccine safety and effectiveness in subpopulations [PDF]
This dissertation examines post-licensing vaccine safety and effectiveness against two major respiratory diseases in specific subpopulations, with emphasis on safety.
Mak, Tippi
core +1 more source
The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea [PDF]
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination.
Na-Young Jeong +14 more
doaj +1 more source
Comprehensive safety testing is based on experience with prior ...
Knipe, David M. +3 more
openaire +3 more sources
Introduction and objective COVID-19 disease, caused by the SARS-CoV-2 virus, has been recognised as a pandemic by WHO since 11 March 2020.
Przemysław Raczkiewicz +3 more
doaj +1 more source
Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca +104 more
core +1 more source
Identifying adverse reactions following COVID-19 vaccination in Korea using data from active surveillance: a text mining approach [PDF]
OBJECTIVES Unstructured text data collected through vaccine safety surveillance systems can identify previously unreported adverse reactions and provide critical information to enhance these systems.
Hye Ah Lee +11 more
doaj +1 more source
A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Minassian, Angela M +32 more
core +1 more source

